07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

BVdU: Completed Phase II enrollment

SciClone completed enrollment of 153 patients in a double-blind, placebo-controlled, international Phase II trial comparing six cycles of RP101 plus gemcitabine vs. gemcitabine alone. RP101 has Orphan Drug designation to treat pancreatic cancer in the...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

BVdU: Phase II started

SciClone began a double-blind, placebo-controlled, international Phase II trial in 153 patients to evaluate 6 cycles of gemcitabine with or without RP101 for 3 weeks followed by 1 week of rest. The company licensed U.S....
08:00 , Nov 19, 2007 |  BC Week In Review  |  Clinical News

RP101: Phase II start

This quarter, SCLN will start a double-blind, international Phase II trial in 153 patients to evaluate up to six 28-day treatment cycles of RP101 plus gemcitabine or gemcitabine alone. The milestone will trigger a $1.3...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Clinical News

RP101: Phase II start

Early next year, AVTO will begin a double-blind, placebo-controlled Phase II trial comparing RP101 plus gemcitabine with gemcitabine alone Avantogen Oncology Inc. (AVTO), Los Angeles, Calif.   RESprotect GmbH , Dresden, Germany   Product: RP101...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Clinical News

RP101: Phase II start

By early next year, AVTO will begin a Phase II trial comparing 750 mg daily of RP101 plus gemcitabine to gemcitabine plus placebo. Avantogen Oncology Inc. (AVTO), Los Angeles, Calif.   Bioaccelerate Holdings Inc. (BACL),...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Clinical News

RP101: Interim Phase I data

Interim data from an open-label Phase I trial in 22 patients showed that RP101 plus gemcitabine led to survival rates of 68% and 39% at 6 and 12 months, respectively. The estimated median survival was...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Clinical News

RP101: Interim Phase II data

Interim data from an ongoing, 8-month, double-blind, placebo-controlled, German Phase II trial in 22 patients with metastatic pancreatic cancer showed that after 6 months 41% of patients were still alive, 23% had died and 36%...
07:00 , Sep 26, 2005 |  BC Week In Review  |  Clinical News

RP101: Additional Phase I/II data

Additional data from a previously reported open-label, German Phase I/II trial in 13 patients showed that 10 of the 13 patients taking 500 mg daily RP101 plus gemcitabine/cisplatin survived at least 1 year. The median...
08:00 , Feb 14, 2005 |  BC Week In Review  |  Clinical News

RP101: Phase I/II data

Data from an open-label, German Phase I/II trial in 13 patients showed that RP101 plus gemcitabine/cisplatin increased the 50% probability of survival by about an average of 15 months compared to a historic average of...